Canaccord Genuity Group Has Lowered Expectations for Perrigo (NYSE:PRGO) Stock Price

Perrigo (NYSE:PRGO) had its price objective decreased by equities researchers at Canaccord Genuity Group from $20.00 to $17.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. Canaccord Genuity Group’s price objective indicates a potential upside of 28.54% from the company’s current price.

Several other research firms have also commented on PRGO. Zacks Research raised shares of Perrigo from a “strong sell” rating to a “hold” rating in a research note on Friday, February 13th. Wall Street Zen lowered shares of Perrigo from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Argus upgraded shares of Perrigo to a “hold” rating in a report on Wednesday, January 14th. Jefferies Financial Group reissued a “hold” rating on shares of Perrigo in a research report on Thursday. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Perrigo in a research report on Monday, December 22nd. One research analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $19.33.

Perrigo Stock Down 6.8%

Shares of NYSE:PRGO opened at $13.23 on Friday. The company has a market cap of $1.82 billion, a price-to-earnings ratio of -1.29, a PEG ratio of 1.19 and a beta of 0.39. Perrigo has a 12 month low of $12.17 and a 12 month high of $30.93. The company has a current ratio of 2.51, a quick ratio of 1.44 and a debt-to-equity ratio of 0.81. The company has a 50-day moving average price of $14.41 and a 200 day moving average price of $17.45.

Perrigo (NYSE:PRGO) last posted its quarterly earnings data on Thursday, February 26th. The company reported $0.77 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.80 by ($0.03). The company had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.09 billion. Perrigo had a negative net margin of 33.51% and a positive return on equity of 8.62%. Perrigo’s revenue for the quarter was down 2.5% on a year-over-year basis. During the same period in the previous year, the business earned $0.93 earnings per share. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. As a group, equities research analysts predict that Perrigo will post 2.56 earnings per share for the current year.

Hedge Funds Weigh In On Perrigo

Institutional investors have recently made changes to their positions in the company. State of Michigan Retirement System raised its holdings in shares of Perrigo by 1.2% in the second quarter. State of Michigan Retirement System now owns 33,058 shares of the company’s stock valued at $883,000 after acquiring an additional 400 shares in the last quarter. Amundi increased its position in Perrigo by 11.7% during the 1st quarter. Amundi now owns 5,292 shares of the company’s stock valued at $148,000 after purchasing an additional 556 shares during the period. Slocum Gordon & Co LLP raised its holdings in shares of Perrigo by 1.1% in the 3rd quarter. Slocum Gordon & Co LLP now owns 53,253 shares of the company’s stock valued at $1,186,000 after purchasing an additional 602 shares in the last quarter. Hantz Financial Services Inc. lifted its position in shares of Perrigo by 101.0% in the 2nd quarter. Hantz Financial Services Inc. now owns 1,234 shares of the company’s stock worth $33,000 after purchasing an additional 620 shares during the period. Finally, Kestra Investment Management LLC boosted its stake in shares of Perrigo by 57.1% during the second quarter. Kestra Investment Management LLC now owns 1,766 shares of the company’s stock valued at $47,000 after purchasing an additional 642 shares in the last quarter. Hedge funds and other institutional investors own 95.91% of the company’s stock.

More Perrigo News

Here are the key news stories impacting Perrigo this week:

• Positive Sentiment: Analyst support remains: Canaccord trimmed its price target from $20 to $17 but kept a “buy” rating, signaling some analysts still see upside versus the current share level. Canaccord price target note (Benzinga)
• Positive Sentiment: Company execution items: Perrigo says FY2025 adjusted EPS landed at the midpoint of its updated outlook, advanced a “3‑S” commercial plan, gained share in OTC/store‑brand categories, and launched operational savings expected to deliver $80–$100M pre‑tax annualized — all items that support longer‑term margin recovery. PR Newswire: FY2025 results & initiatives
• Neutral Sentiment: Analyst/investor materials available — full earnings call transcript and slide deck were published for investors who want details on segment reporting changes and management commentary. Reviewing these can help assess whether guidance and the formula exposure are temporary. Earnings call transcript/highlights (Yahoo)
• Negative Sentiment: Q4 miss on EPS: Perrigo reported $0.77 EPS vs. consensus ~$0.80 and EPS is down year‑over‑year (prior $0.93), which eroded near‑term investor confidence despite a slight revenue beat. Zacks: Q4 earnings miss & analysis
• Negative Sentiment: Weaker FY2026 outlook: Management set FY2026 EPS guidance at $2.25–$2.55 (below the ~$2.70 consensus) and reiterated revenue guidance below/at consensus, explicitly calling out Infant Formula as a drag and introducing a ‘CORE’ view that excludes formula/divestitures — the guidance shortfall and exposed category risk are the main reasons the stock is down. Zacks: weak 2026 guidance & formula headwinds

About Perrigo

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.